Chemical detection company MyDx Inc (OTC:MYDX) disclosed on Thursday the appointment of Jessica Peatross as its chief medical officer.
In the company's medical department, Dr Peatross will lead the clinical research initiatives, support formulation services to MyDx360 Customers, as well as offer doctor consultation for its customers through the MyDx App, including the possibility of writing medical cannabis prescriptions in all legal states.
Currently, Dr Peatross is a western trained, board certified medical doctor, a Gerson Therapy practitioner, a consultant in San Diego's premiere Nourish Medical Center as well as owns and operates an organically formulated nutraceutical line of products tailored to treating various chronic symptoms and illnesses.
Previously, Dr Peatross worked as a traditional doctor supporting patients in a level 1 trauma centre for six years as well as practised functional medicine with Optimal Health and Wellness and Whitiker Wellness.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study